nature neurOSCIenCe a r t I C l e S RTT is an autism spectrum disorder that is caused by mutations in the X-linked gene encoding methyl-CpG binding protein 2 (MeCP2) 1 . RTT is associated with different types of mutations in MECP2, including missense, nonsense, deletions and insertions 2 . Individuals with classical RTT, irrespective of the type of mutation, develop normally for the first 6-18 months of age, after which they enter a period of regression that is characterized by deceleration of head growth and a loss of acquired motor and language skills. Frequently, affected individuals develop stereotypic hand wringing, abnormal breathing, seizures and autistic behaviors 3 . The molecular mechanisms through which different types of MECP2 mutations lead to disruptions in proper brain function are not fully understood.
a r t I C l e S
RTT is an autism spectrum disorder that is caused by mutations in the X-linked gene encoding methyl-CpG binding protein 2 (MeCP2) 1 . RTT is associated with different types of mutations in MECP2, including missense, nonsense, deletions and insertions 2 . Individuals with classical RTT, irrespective of the type of mutation, develop normally for the first 6-18 months of age, after which they enter a period of regression that is characterized by deceleration of head growth and a loss of acquired motor and language skills. Frequently, affected individuals develop stereotypic hand wringing, abnormal breathing, seizures and autistic behaviors 3 . The molecular mechanisms through which different types of MECP2 mutations lead to disruptions in proper brain function are not fully understood.
Mice engineered with different Mecp2 alterations have phenotypes that are both similar and distinct from those observed in Mecp2 null mice [4] [5] [6] [7] [8] [9] [10] [11] . These similarities and differences in mouse models suggest that different MECP2 mutations are likely to have both shared and distinct biochemical and physiological correlates. Notably, reintroduction of MeCP2 into behaviorally affected Mecp2 null mice is sufficient to rescue RTT-like phenotypes 12 , and restoration of MeCP2 function in astrocytes alone substantially improves the developmental outcome of Mecp2 −/y mice 13 , suggesting that RTT is reversible after restoration of MeCP2 function. Thus, understanding the mechanisms by which different MeCP2 mutations lead to RTT may reveal effective strategies that are tailored to the particular mutation to restore MeCP2 function.
Mutation of the T158 residue, located at the C terminus of the methyl-CpG binding domain (MBD) of MeCP2, represents one of the most common mutations observed in RTT. Approximately 10% of all RTT cases carry a single nucleotide mutation converting T158 to methionine (T158M) or, in rare cases, to alanine (T158A) 2 . It has been suggested that the T158 residue is important for the stabilization of the MBD and the binding of MeCP2 to methylated DNA 14 . Whether mutation of T158 leads to MeCP2 gain-of-function or loss-offunction, however, is not clear.
The onset of RTT symptoms occurs during the establishment and refinement of neural networks in early postnatal development. Studies in Mecp2 null mice have suggested that reductions in connectivity between excitatory pyramidal neurons are associated with RTTlike phenotypes [15] [16] [17] . The means by which reductions in neuronal connectivity lead to the manifestation of the age-dependent cognitive and behavioral deficits in RTT are currently unknown. Cognitive dysfunctions are frequently assessed by measuring the neurophysiological responses that occur during passive processes or during the performance of cognitive, sensory or motor tasks. Brain activations that occur during these tasks manifest as ERPs. Disruptions in ERPs and the oscillations that underlie them are associated with a number of cognitive disorders, such as schizophrenia 18, 19 and autism 20, 21 . Electroencephalography (EEG) recordings in Mecp2 −/y mice 22, 23 and ERP recordings in individuals with RTT 24,25 also suggest that alterations in brain activity are associated with behavioral and cognitive deficits. How ERPs are affected by MeCP2 dysfunction and how changes in EEG and ERPs correlate with the age-dependent progression of RTT-like symptoms, however, remain to be determined.
Given the high frequency of T158 mutations in RTT and its role in methyl-DNA binding, we sought to model this mutation in vivo and developed knockin mice containing the T158A mutation (Mecp2 T158A/y mice). We found that these mice recapitulate a number a r t I C l e S of RTT-like symptoms observed in Mecp2 null mice, including late onset of hypoactivity, poor motor control, irregular breathing, altered anxiety, impaired learning and memory, and shortened lifespan. We found that T158A mutation decreased the binding of MeCP2 to methylated DNA in vitro and in vivo, and reduced MeCP2 protein stability. Moreover, the amplitude and latency of ERPs in both Mecp2 T158A/y and Mecp2 −/y mice were substantially altered. Time-frequency analysis of these ERPs revealed that Mecp2 T158A/y mice failed to show a developmental increase in event-related power and phase locking as compared with wild-type mice, indicating that MeCP2 is required for the development of functional neuronal circuits. Our results suggest that stabilization of MeCP2 protein and enhancement of its affinity for methylated DNA may provide a potential therapeutic approach for treating individuals with a MeCP2 T158 mutation. Furthermore, assessment of ERPs may serve as a biomarker for RTT and the evaluation of therapeutic efficacy in RTT treatment.
RESULTS

Generation of
Mecp2 T158A/y and Mecp2 loxP/y mice Although the T158A mutation occurs at a lower frequency than the T158M mutation in individuals with RTT, the mechanism by which both mutations impair MeCP2 function is believed to be the same: the lack of hydroxyl group in alanine and methionine destabilizes the tandem Asx-ST motif in the MBD and thereby reduces MeCP2 affinity for methylated DNA 14 . Indeed, individuals carrying MeCP2 T158A or T158M mutations are phenotypically similar in the identity and severity of presented symptoms 26, 27 . To examine the importance of the T158 residue in MeCP2 function, we developed a knockin mouse with a T158A mutation to circumvent the potential steric interference brought about by the larger methionine residue. To facilitate screening of properly targeted embryonic stem (ES) cells, we incorporated a silent mutation at codon 160 to create a new BstEII restriction site and a loxP-flanked neomycin expression cassette in intron III of the Mecp2 gene (Supplementary Fig. 1 ). Given that our goal was to test a rather subtle mutation on MeCP2, a single amino acid change of T158A, we also engineered loxP knockin mice (Mecp2 loxP/y ), which contained the BstEII restriction site and loxP insertion, but lacked the T158A mutation, to rule out the possibility that manipulation of the Mecp2 locus may affect MeCP2 expression (Supplementary Fig. 1) .
Sequencing of MeCP2 mRNA extracted from brain tissues of wild-type, Mecp2 T158A/y and Mecp2 loxP/y mice verified that both Mecp2 T158A/y and Mecp2 loxP/y mice contained the thymine to cytosine mutation at codon 160 for the generation of the BstEII restriction site, whereas only Mecp2 T158A/y mice contain the adenine to guanine mutation at codon 158 (Fig. 1a) . Furthermore, a MeCP2 T158 site-specific antibody recognized MeCP2 protein from wild-type and Mecp2 loxP/y mice, but not from Mecp2 T158A/y mice, confirming the successful generation of Mecp2 T158A/y mice (Fig. 1b) .
Mecp2 T158A/y mice recapitulate RTT-like phenotypes RTT is characterized by relatively normal development during the first 6-18 months of life, followed by a period of developmental stagnation leading to motor impairments, breathing abnormalities and intellectual disability. We evaluated the presence, development and progression of RTT-like phenotypes in MeCP2 T158A mice following a previously reported scoring system 12 . Male Mecp2 T158A/y mice presented no overt symptoms during the first 4 weeks of life, but became progressively symptomatic after 5 weeks of age, as indicated by an increasing phenotypic score (Fig. 1c) . The hindlimb clasping apparent in Mecp2 −/y mice was also observed in Mecp2 T158A/y mice npg a r t I C l e S ( Supplementary Fig. 2a ). Mecp2 T158A/y mice weighed significantly less than their wild-type littermates starting from 4 weeks of age (P < 0.0001), but then gradually gained weight until they reached wildtype levels at 8 weeks of age ( Supplementary Fig. 2b ). In contrast, the body weights of Mecp2 loxP/y mice were indistinguishable from their wild-type littermates (data not shown). Occasionally, we observed seizure behaviors in Mecp2 T158A/y mice after 5 weeks of age. Given that MECP2 is an X-linked gene and that the majority of individuals with RTT are girls with mosaic MeCP2 expression resulting from random X-chromosome inactivation, female Mecp2 T158A/+ mice represent a close genetic match to individuals with RTT. Phenotypic scoring revealed no apparent symptoms in these mice until 17 weeks of age, after which they became progressively and increasingly symptomatic (Fig. 1d) . A significant increase in body weight also occurred in female Mecp2 T158A/+ mice at the time of symptom presentation (P < 0.05; Supplementary Fig. 2c ), similar to that observed in heterozygous Mecp2 −/+ female mice 12 .
An early diagnostic criterion for RTT is a deceleration in head growth, which often leads to microcephaly by the first 2 years of life 3, 28 . We observed a significant reduction in the sizes and weights of brains of presymptomatic (postnatal day 30, P30) and postsymptomatic (P90) Mecp2 T158A/y mice relative to their wild-type littermates (P < 0.01; Fig. 1e ), similar to that observed in Mecp2 −/y mice 4, 5 . The gross brain anatomy of Mecp2 T158A/y mice, however, was indistinguishable from that of their wild-type littermates ( Supplementary  Fig. 2d ). The decreased brain size and weight in Mecp2 −/y mice are purported to occur, at least in part, through a reduction in neuronal soma size 4, 28 . To assess whether soma size is affected in Mecp2 T158A/y mice, we bred Mecp2 T158A/y mice to mice expressing GFP under the control of the Thy1 promoter 29 . Focusing on the hippocampal CA1 region, confocal imaging of GFP-positive pyramidal neurons revealed a significant reduction in soma size in Mecp2 T158A/y mice compared with wild-type littermates at both P30 and P90 (P < 0.01; Fig. 1f ).
MeCP2 mutation in boys often leads to infantile lethality 3 and male Mecp2 −/y mice had shortened lifespans 4, 5, 8 . We found that male Mecp2 T158A/y mice died prematurely, with 50% dying by 16 weeks of age (Fig. 1g) , approximately 3-4 weeks later than germline Mecp2 −/y mice 4, 5 . No apparent changes in the survival profiles of female Mecp2 T158A/+ mice were observed before 6 months of age (data not shown). Notably, we did not observe any difference in longevity, body weights or brain weights of Mecp2 loxP/y mice, supporting the conclusion that these changes are the result of T158A mutation (data not shown). Together, these data suggest that mice carrying the MeCP2 T158A mutation manifest RTT-like phenotypes.
Mecp2 T158A/y mice present similar phenotypes as Mecp2 −/y mice Given the clinical relevance of the MeCP2 T158A mutation, we sought to carry out a side-by-side comparison of behavioral phenotypes with a well-studied Mecp2 −/y mouse 5 . In light of the locomotor deficits, aberrant gait and hindlimb clasping observed in these mice (Supplementary Video 1), we assessed locomotor activity in a home cage environment with a cohort of age-matched wild-type, Mecp2 T158A/y and Mecp2 −/y littermates on the same C57BL/6 background at approximately 9 weeks of age. We found a significant reduction in the locomotor activity of both Mecp2 T158A/y (P < 0.01) and Mecp2 −/y (P < 0.001) mice as compared with wild-type littermates (Fig. 2a) . However, the reduction in locomotor activity was significantly higher in Mecp2 −/y mice than in Mecp2 T158A/y mice (P < 0.01; Fig. 2a) . We also found a significant reduction in the distance traveled by Mecp2 T158A/y mice at 11 (P < 0.05), but not 3, weeks as compared with wild-type littermates using the open field assay (Supplementary Fig. 3a) . Similarly, locomotor activity was also significantly reduced in female Mecp2 T158A/+ mice at 20 (P < 0.05), but not 12, weeks of age ( Supplementary Fig. 3b) , consistent with the agedependent hypoactivity observed with phenotypic scoring (Fig. 1c,d ).
To examine motor coordination and motor learning in these two mouse models, we performed the accelerating rotarod test. Wild-type mice showed an increase in the latency to fall over the course of four trials per day for 4 d, indicating improvements in motor coordination and learning over time (Fig. 2b) . However, both Mecp2 T158A/y and Mecp2 −/y mice spent significantly less time on the rotarod than wild-type littermates (P < 0.0001) and failed to improve over the course of 4 d, suggesting that they had deficits in motor coordination and motor learning (Fig. 2b) . The latency to fall from the rotarod was moderately, but significantly, decreased in Mecp2 −/y mice compared with Mecp2 T158A/y mice (P < 0.0001; Fig. 2b ). We conclude that the MeCP2 T158A mutation impairs motor function similar to that seen in individuals with RTT and to a lesser degree than that seen in Mecp2 null mice.
Individuals with RTT experience anxiety episodes, particularly in response to distressing events 3 . The role of MeCP2 in anxiety in mice, however, is less clear. Mecp2 null mice and mice with a 50% reduction in MeCP2 protein expression both show a decreased anxiety phenotype [8] [9] [10] , whereas those containing an early-truncating mutation show increased anxiety 6 . Using the elevated zero maze procedure, we found that Mecp2 T158A/y and Mecp2 −/y mice spent and Mecp2 +/y littermates (wild type, n = 33) at 9 weeks of age. Bars represent mean ± s.e.m. **P < 0.01 and ***P < 0.001 versus Mecp2 T158A/y , ## P < 0.001 versus wild type, oneway ANOVA with Tukey's post hoc test. (b) Motor coordination and motor learning was assessed using a rotarod assay in Mecp2 T158A/y mice (n = 16, F 1,645 = 447.2, P < 0.0001, twoway ANOVA) and Mecp2 −/y mice (n = 14, F 1,602 = 841.46, P < 0.0001, twoway ANOVA) and Mecp2 +/y littermates (n = 27) at 9 weeks of age. The deficit in Mecp2 −/y mice was significantly more than that observed in Mecp2 T158A/y mice (F 1,437 = 83.82, P < 0.0001, twoway ANOVA). Symbols represent mean ± s.e.m. (c) Anxietylike behavior in Mecp2 T158A/y mice (n = 15) and Mecp2 −/y mice (n = 11) was measured using elevated zero maze and compared with that of Mecp2 +/y littermates (n = 32) at 9 weeks of age. Bars represent mean ± s.e.m. *P < 0.05 and **P < 0.01, oneway ANOVA with Tukey's post hoc test. (d) Learning and memory assessed using context and cuedependent fear conditioning in Mecp2 T158A/y mice (n = 16) and Mecp2 +/y littermates (n = 33) at 10 weeks of age. Bars represent mean ± s.e.m. *P < 0.05 and ***P < 0.001, twotailed ttest with Bonferroni correction. Because RTT is the primary cause of intellectual disability in females, we examined whether MeCP2 mutant mice have learning and memory deficits using contextual and cued fear-conditioning procedures. Mice were trained to associate a context (testing box) and a cue (auditory tone) with a co-terminating foot shock. Mice typically freeze in response to the shock. We found no differences in freezing behaviors in wild-type and Mecp2 T158A/y littermates before or immediately following shocks, suggesting that there were no differences in pain sensitivity. However, Mecp2 −/y mice exhibited significantly increased freezing even before the shock (P < 0.01; Supplementary Fig. 3c ). This is likely a result of their decreased locomotor activity and akinesia, thus confounding interpretation of the fear-conditioning test. These mice were therefore excluded from this study. Mecp2 T158A/y mice showed significantly less context-dependent (P < 0.05) and cue-dependent (P < 0.001) freezing than their wild-type littermates at 24 h after training, suggesting that they have deficits in learning and memory (Fig. 2d) .
Together, these findings indicate that Mecp2 T158A/y mice have phenotypes similar to those observed in Mecp2 −/y mice, but to a lesser extent overall. We therefore infer that T158A is a partial loss-offunction mutation.
Decreased MeCP2 protein stability in Mecp2 T158A/y mice Alterations in MeCP2 protein levels, such as a 50% reduction or a twofold increase, leads to the progressive development of neurological deficits in mice, albeit at much later time points than those observed in Mecp2 null mice 7,9,10 . We therefore examined whether the T158A mutation alters the expression of MeCP2 protein during development. Quantitative western blotting on whole-cell lysates from the brains of male Mecp2 T158A/y mice revealed that MeCP2 protein expression was significantly decreased at P2, P30 and P90 compared with their wild-type littermates (P < 0.01; Fig. 3a) . The downregulation of MeCP2 expression was significantly higher at P90 (P < 0.05), when Mecp2 T158A/y mice presented overt RTT-like phenotypes, than at either P2 or P30, when symptoms were not present (Fig. 1c) . Notably, MeCP2 protein levels were not affected in Mecp2 loxP/y mice, indicating that the downregulation of MeCP2 is a result of the presence of the T158A mutation rather than of genomic modification (Fig. 1b) . These changes in MeCP2 expression are likely to be independent of gene transcription, as quantitative real-time reverse-transcription PCR (RT-PCR) revealed no differences in the level of Mecp2 mRNA expression between Mecp2 T158A/y and wild-type mice at P0, P30 or P90 (Supplementary Fig. 4 ). Despite RTT being primarily a neurological disorder 3 , MeCP2 is ubiquitously expressed in all mammalian tissues 30 . Indeed, we found that MeCP2 protein levels were decreased to a similar extent in kidney, liver, lung and heart in Mecp2 T158A/y mice (Fig. 3b) .
MeCP2 protein levels were also significantly decreased in the brains of female Mecp2 T158A/+ mice as compared with their wild-type littermates (P < 0.05; Fig. 3c ). The magnitude of MeCP2 downregulation in females was less than that observed in male Mecp2 T158A/y mice and was likely a result of the mosaic expression of MeCP2 T158A in heterozygous Mecp2 T158A/+ mice. To investigate whether mutation at T158 disrupts MeCP2 protein expression in individuals with RTT, we obtained fibroblast cultures derived from an affected female with the T158M mutation and an age-matched female control. We found that npg a r t I C l e S MeCP2 expression was also significantly downregulated by about 40% in cells with the MeCP2 T158M mutation compared with control cells (P < 0.05; Fig. 3c ). These data indicate that T158 mutation, to either alanine or methionine, triggers the downregulation of MeCP2 protein expression in both humans and mice, indicating that the reduction in MeCP2 protein expression may be a contributing factor to RTT.
To investigate whether the reductions in MeCP2 protein levels are a consequence of decreased protein stability, we cultured embryonic day 16 (E16) cortical neurons isolated from wild-type and Mecp2 T158A/y mice and inhibited new protein translation using cycloheximide (CHX). The stability of existing MeCP2 protein was assessed at 0, 3, 6 and 9 h following CHX treatment. We found that MeCP2 protein levels in wild-type neurons remained relatively constant over the course of the 9-h CHX treatment as compared with vehicle-treated cultures (Fig. 3d) . In contrast, MeCP2 T158A protein levels were significantly reduced following 6-and 9-h CHX treatments (P < 0.05; Fig. 3d) , suggesting that the T158A mutation decreased MeCP2 protein levels by increasing its rate of degradation. We did not observe destabilization of other proteins, such as NeuN in T158A mice (Fig. 3d) . Thus, the Mecp2 T158A/y mice have revealed a previously unknown function of T158 in the stabilization of MeCP2 protein in vivo. The reduction in MeCP2 protein stability mediated by the T158A mutation may contribute, at least in part, to the etiology of RTT.
T158A mutation disrupts MeCP2 binding to methylated DNA Located at the 3′ end of the MBD, T158 is believed to be important for stabilizing the tertiary structure of MBD and is critical for the binding of MeCP2 to methylated DNA 14 . We recapitulated these in vitro observations using a Southwestern assay (Fig. 4a) . To examine the role of T158 in the regulation of MeCP2 binding to methylated DNA in vivo, we isolated nuclei from the brains of wild-type and Mecp2 T158A/y mice and performed chromatin immunoprecipitation (ChIP) assays against several known MeCP2-binding loci. MeCP2 has been shown to bind across a 39-kb promoter region of the Bdnf locus tracking methyl-CpG sites 31 . Consistent with this, we found a similar MeCP2-binding pattern in brains from P60 wild-type mice (Fig. 4b) . MeCP2 ChIP over the same region in Mecp2 T158A/y brains, however, revealed a 70-75% reduction in MeCP2 binding across the entire locus (Fig. 4b) , suggesting that the T158A mutation decreases MeCP2 binding at methylated DNA. To validate this finding, we also analyzed the binding of MeCP2 to the Xist, Snrpn and Crh loci, which are known MeCP2-binding targets 31, 32 , and found that the binding of MeCP2 at these loci was significantly reduced by approximately 70% in Mecp2 T158A/y brains (P < 0.001; Fig. 4c) . Thus, the reduction of MeCP2 binding at the Bdnf, Xist, Snrpn and Crh loci likely reflects a decreased binding of MeCP2 T158A to methylated DNA together with reduced MeCP2 protein expression.
We reasoned that if MeCP2 T158A has a reduced affinity for methylated DNA in vivo, wild-type or MeCP2 T158A protein would be extracted differently from nuclei under the same salt conditions. To biochemically assay the reduced affinity of MeCP2 T158A to methylated DNA, we isolated neuronal nuclei from either wildtype or Mecp2 T158A/y mouse brains and treated them with increasing concentrations of NaCl to extract proteins into the supernatant. Quantitative western blot analysis revealed that MeCP2 T158A protein was extracted more readily than wild-type protein under low-salt conditions of 250 mM and 300 mM NaCl (Fig. 4d) . When the salt npg a r t I C l e S concentration was raised to above 350 mM, both wild-type and T158A protein were extracted to a similar degree. Thus, the T158A mutation appears to decrease the affinity of MeCP2 for DNA. MeCP2 predominantly associates with heterochromatic foci in mouse cell nuclei in an MBD-and DNA methylation-dependent manner, resulting in a characteristic punctate pattern of nuclear staining 33 . Indeed, MeCP2 immunoreactivity was observed throughout the nucleus, with particularly high enrichment at heterochromatin-dense foci in nuclei from P90 wild-type neurons (Fig. 4e) . In contrast, in nuclei from P90 Mecp2 T158A/y neurons, MeCP2 was markedly diffuse with a clear absence of co-localization with DNA, indicating that the binding of MeCP2 to methylated DNA was disrupted (Fig. 4e) . It is unlikely that this difference is a result of changes in heterochromatin formation, as no overt differences were seen in DNA staining in Mecp2 T158A/y mice. We observed similar immunoreactivity patterns in P30 Mecp2 T158A/y mice before symptom presentation (data not shown). Furthermore, MeCP2 immunoreactivity in female Mecp2 T158A/+ mice revealed a mosaic expression of MeCP2, with approximately 50% of nuclei showing MeCP2 immunoreactivity at heterochromatin-dense foci and the remaining exhibiting diffuse immunoreactivity (Fig. 4f) , as would be expected as a result of random X-chromosome inactivation. Notably, the intensity of MeCP2 immunoreactivity was decreased in Mecp2 T158A/y neurons compared with wild-type neurons, consistent with a reduction of MeCP2 T158A protein expression. Together, these findings suggest that the T158A mutation impairs the binding of MeCP2 to methylated DNA in vivo and contributes, at least in part, to the etiology of RTT.
Disruption of transcription by MeCP2 T158A
Transcriptional profiling of RNA isolated from the hypothalamus or cerebellum of Mecp2 −/y mice revealed changes in the expression of hundreds of genes 32 . We analyzed the expression of a few representative targets, such as Bdnf, Crh and Sgk, using quantitative RT-PCR and found that both Bdnf and Crh transcription were significantly reduced in the hypothalamus, but not striatum, of Mecp2 T158A/y mice (P < 0.05; Fig. 5a,b) , whereas Sgk, a gene that is upregulated in Mecp2 −/y mice 34 , was elevated in the striatum, but not in the hypothalamus, of Mecp2 T158A/y mice (Fig. 5a,b) . These data support the idea that gene transcription is similarly disrupted in Mecp2 T158A/y and Mecp2 −/y mice in a tissue-and/or cell type-specific manner.
MeCP2 has been shown to regulate gene transcription through its interaction with histone deacetylases (HDACs) 1 and 2 and the co-repressor Sin3a 35, 36 . It is conceivable that the T158A mutation may disrupt the ability of MeCP2 to associate with these proteins through alterations in the conformation of MeCP2 and thus disrupt downstream gene regulation. We therefore performed co-immunoprecipitation experiments using an antibody to MeCP2 in nuclear extracts prepared from wild-type and Mecp2 T158A/y brains. Consistent with previous findings, wild-type MeCP2 interacted with HDAC1 and Sin3a (Fig. 5c) . MeCP2 T158A also associated with HDAC1 and Sin3A, albeit at a reduced level, consistent with the reduction in MeCP2 T158A protein expression (Fig. 5c) . These data support the idea that MeCP2 T158A protein retains the ability to interact with the co-repressor proteins. Thus, we conclude that the T158A mutation leads to a deregulation of gene expression through reduced DNA binding and MeCP2 protein stability.
Age-dependent alterations in EEG and ERP recordings
The manifestations of symptoms in individuals with RTT and Mecp2 null mice are thought to occur in part because of alterations in neural network activity. Given that RTT symptoms appear at certain developmental time points, we sought to investigate the neural mechanisms underlying age-dependent exhibition of phenotypes in Mecp2 T158A/y mice. Thus, we performed EEG recordings in wild-type and Mecp2 T158A/y mice at two developmental time periods, P30 and P90; that is, before and subsequent to the establishment of RTT-like symptoms. EEG recordings in awake, freely mobile mice revealed a significant increase in the power of high-gamma frequency (γ high , 70-140 Hz) oscillations in Mecp2 T158A/y mice at P90 compared with wild-type littermates (P < 0.001; Fig. 6a,b) . A similar increase in γ high power was also observed in symptomatic Mecp2 −/y mice ( Supplementary Fig. 5a,b) . γ high activity is known to be associated with epilepsy in the EEG before and during seizure 37 and may reflect an overall hyperexcitability in the brains of Mecp2 T158A/y and Mecp2 −/y mice 22 . However, we did not observe an increase in γ high power in presymptomatic Mecp2 T158A/y mice at P30 (Supplementary Fig. 6a,b) , suggesting that MeCP2 dysfunction induces hyperexcitability in the brain in an age-dependent manner.
In addition to measuring electrical activity during passive processes, it is also possible to measure those that occur during the performance of a cognitive, sensory or motor task. The manifestation of these brain activities is recorded as a series of amplitude deflections in the EEG as a function of time and is referred to as an ERP. ERPs are small compared with the background EEG, but can be resolved by averaging single trial epochs. They are characterized as voltage deflections defined by latency and polarity, where the amplitude and latency of the polarity peaks are believed to reflect the strength and timing of the cognitive processes related to the event. Notably, individuals with RTT, as well as those with schizophrenia and autism, show alterations in both the amplitudes and latencies of ERPs [19] [20] [21] 24, 25 .
To examine ERP responses in Mecp2 T158A/y mice, we performed EEG recordings following the presentation of a series of white noise clicks. We chose to perform auditory-evoked ERP assessments because they can be performed on freely mobile mice and are not confounded by the motor or attentional deficits associated with MeCP2 dysfunction. The ERP was extracted by averaging the EEG traces over single trial epochs. ERPs in wild-type and Mecp2 T158A/y mice showed a stereotypical initial positive peak (P1), followed by a negative peak (N1) and a subsequent second positive peak (P2) (Fig. 6c) . Notably, we found significant increases in the latency of P1 (P < 0.05), N1 and P2 peaks (P < 0.01) and significant reductions in the amplitudes of the N1 and P2 peaks (P < 0.05) in symptomatic P90 Mecp2 T158A/y mice compared with wild-type littermates (Fig. 6c-e) . Similar alterations in ERP amplitudes and latencies were observed in Mecp2 −/y mice (Supplementary Fig. 5c-e) . However, we observed no effect on ERPs in Mecp2 T158A/y mice at P30, before the establishment of RTT-like symptoms (Supplementary Fig. 6c-e) . Notably, we found no differences in hearing sensitivities between Mecp2 T158A/y mice or Mecp2 −/y mice and their wild-type littermates as measured by auditory brain stem responses, suggesting that these disruptions in ERP are a result of alterations in cortical processing of sensory input (Supplementary Fig. 7 ). These data suggest that the neural networks underlying information processing are disrupted by MeCP2 dysfunction in an age-dependent manner, corresponding to the behavioral onset of symptoms.
Progressive alterations in event-related power and PLF One limitation of time-amplitude analysis of ERPs is that oscillatory information that is not time-locked to the stimulus is lost through signal averaging. Using time-frequency analysis, it is possible to analyze changes in oscillatory activity as a function of time and thus gain additional insight into the underlying brain activity and circuitry. Oscillatory responses during the performance of tasks are characterized by the average power and phase locking across trials 38 . The degree of event-related power and phase locking at different frequencies may reflect the strength and connectivity of local (at high frequencies) and long-range (at low frequencies) neuronal circuits 39 .
Thus, we next performed time-frequency analysis on EEG recordings used to determine auditory-evoked ERPs. We found that wild-type mice at P90 showed a significant depression in the mean power of oscillations in the low-frequency delta (δ, 2-4 Hz), theta (θ, 4-8 Hz) and alpha (α, 8-12 Hz) ranges on auditory stimulation (Fig. 7a,b) . The mean event-related power of highfrequency beta (β, 12-30 Hz), low gamma (γ low , 30-50 Hz) and γ high (70-140 Hz) increased following the auditory stimulus and was followed by a sustained depression in power (Fig. 7a,b) . Notably, these changes were sustained for a number of oscillation cycles at all frequencies and outlasted the transient ERP response, reflecting an effect in both evoked and ongoing oscillatory processes (Fig. 7a,b) . Overlaying the ERP with band-pass EEG traces at each frequency range also revealed the oscillatory information in the transient ERP response (Supplementary Fig. 8 ). Mecp2 T158A/y mice, however, exhibited significantly attenuated event-related power in both low-and highfrequency oscillations at P90 (P < 0.001), when RTT-like symptoms were overt (Fig. 7a,b and Supplementary Fig. 9a) . Similarly, highly symptomatic Mecp2 −/y mice showed significantly reduced eventrelated power following auditory stimulation at all frequencies (P < 0.001; Supplementary Figs. 9b and 10a,b) . Notably, we also found a small, but significant, reduction in event-related power in low-frequency δ, θ and α in P30 Mecp2 T158A/y mice prior to symptom onset compared with wild-type littermates (P < 0.05), in contrast with that observed using time-amplitude analysis (Supplementary Figs. 9c  and 11a,b) . These data suggest that the underlying deficits in neural activity occur before the establishment of behavioral symptoms, consistent with in vitro electrophysiological studies showing reduced cortical excitability in Mecp2 −/y mice even at 2-3 weeks of age 15 . npg a r t I C l e S Time-frequency analysis also allows for the calculation of oscillation phase locking across trials. The phase-locking factor (PLF) quantifies the trial-to-trial reliability of oscillation phase, with a high PLF corresponding to a low circular variance in oscillation phase as a function of time between trials. A high PLF is thought to reflect the reliability and sensitivity of communications between circuits in the brain 40 . We found that wild-type mice at P90 showed increases in PLF at all frequencies in response to the presentation of auditory stimuli (Fig. 7c,d) . The increase in PLF in Mecp2 T158A/y mice at P90, however, was significantly reduced compared with that of wild-type mice (P < 0.01 for θ, α and γ low , P < 0.001 for δ, β and γ high ; Fig. 7c,d and Supplementary Fig. 9d) . A significant reduction in event-related PLF in Mecp2 −/y mice was also observed (P < 0.05 for γ low , P < 0.01 for θ, α and β, P < 0.001 for δ and γ high ), consistent with the expression of RTT-like phenotypes in both groups of mice ( Supplementary Figs. 9e and 10c,d) . We detected significant attenuation in PLF in presymptomatic P30 Mecp2 T158A/y mice, but only at δ and γ high frequencies (P < 0.05; Supplementary Figs. 9f and 11c,d) .
Notably, the fact that we did not observe changes in ERP amplitudes at P30 in Mecp2 T158A/y mice (Supplementary Figs. 6 and 12) suggests that time-frequency analysis of event-related power and PLF represents a sensitive approach for probing neural function in vivo.
When comparing the event-related neuronal responses in wild-type mice at two developmental stages, we found that event-related power at all frequencies and PLF at high frequencies were significantly higher in P90 mice than in P30 mice (P < 0.05 for β and γ low , P < 0.01 for γ high ; Fig. 8a,b) . This likely reflects the development and maturation of the underlying neuronal circuitry. In contrast, Mecp2 T158A/y mice did not show a developmental increase in either event-related power (Fig. 8c) or phase locking (Fig. 8d) from P30 to P90, suggesting an impairment in age-dependent neural network maturation. These agedependent differences were observed using time-frequency analysis, but not using time-amplitude analysis ( Fig. 8 and Supplementary  Fig. 12 ). Together, these data suggest that MeCP2 is important for the regulation of event-related neuronal responses and is required for the maturation and restructuring of neural networks. The disruptions in npg a r t I C l e S event-related power and PLF may therefore contribute to the deficits in behavioral and cognitive functions that are observed in RTT. We propose that ERP studies may serve as a sensitive biomarker for the evaluation of treatments in individuals with RTT.
DISCUSSION
Mutation of threonine 158 to methionine or, in rare cases, alanine in MeCP2 represents one of the most common mutations observed in individuals with RTT 2 . Previous in vitro experiments have established a critical role for this residue in the binding of MeCP2 to methylated DNA. To address the causal role of the T158A mutation in the pathogenesis of RTT and the role of methyl-DNA binding in the proper functions of MeCP2, we developed and characterized Mecp2 T158A/y mice. We found that Mecp2 T158A/y mice developed normally for the first 4-5 weeks of life, after which they presented RTT-like symptoms, including decreased motor performance, altered anxiety, aberrant gait, hindlimb clasping, breathing abnormalities, and impaired learning and memory. The similarity in the identity and severity of symptoms with those observed in Mecp2 null mice indicates that the T158A mutation is a partial loss-of-function mutation.
The development of this mouse line allowed us to investigate the biochemical consequences of the T158A mutation in vivo. Consistent with previous in vitro studies, we found that the T158A mutation led to a reduction in the affinity of MeCP2 for methylated DNA in vivo. Notably, we also observed that the T158A mutation concomitantly decreased MeCP2 protein expression in vivo. Consistent with these data, we found that fibroblasts obtained from a woman with RTT carrying the MeCP2 T158M mutation expressed decreased levels of MeCP2 protein. These findings reveal two consequences of T158 mutation: impaired MeCP2 binding to DNA and decreased MeCP2 protein stability.
Previous studies have shown that MeCP2 protein levels must be tightly regulated to ensure its proper function. A 50% reduction in MeCP2 protein expression leads to progressive neurological symptoms 9,10 , although symptoms appear later and do not fully recapitulate the RTT-like symptoms seen in Mecp2 null mice. Thus, the destabilization of MeCP2 protein alone, as observed in our Mecp2 T158A/y mice, may not be sufficient to cause the RTT-like symptoms. We propose that the combined reduction in MeCP2 protein levels and the decreased binding to methylated DNA contribute to the loss-of-function phenotype in Mecp2 T158A/y mice. The development of knockin mice carrying other mutations that disrupt DNA binding will provide further insights into this hypothesis. Given that the reintroduction of MeCP2 protein into Mecp2 null mice is sufficient to rescue RTT-like phenotypes 12 , we suggest a dual approach to restore MeCP2 function in individuals carrying MeCP2 T158 mutations: increasing MeCP2 affinity for methylated DNA and enhancing MeCP2 protein stability. Indeed, the feasibility of increasing affinity for DNA has been shown for other DNA-binding proteins such as p53 (ref. 41) . It is conceivable that increasing MeCP2 affinity for methylated DNA may help to stabilize MeCP2 protein expression. Utilizing one or both of these approaches may lead to the amelioration of RTT-like phenotypes. Our findings also suggest that different therapeutic strategies should be considered for treating individuals with different MeCP2 mutations.
Given their neurological origin, many of the symptoms associated with RTT have been hypothesized to result from imbalanced neural networks 3 . Evidence to support this arises from observed alterations in synaptic connectivity and plasticity 12, [15] [16] [17] 42 and hyperexcitability in the EEGs 22, 23 of Mecp2 −/y mice. Furthermore, ERP analysis in women with RTT suggests that alterations occur in the sensory processing of information 24, 25 . Given the delayed onset of symptoms in individuals with RTT, Mecp2 T158A/y mice and Mecp2 −/y mice, we sought to examine whether neurophysiological responses, as measured by EEG, are altered during development in Mecp2 T158A/y mice. Indeed, we found that the power of γ high EEG signals was substantially increased in Mecp2 T158A/y mice when these mice exhibited RTT-like symptoms, suggesting hyperexcitability in the brain. Furthermore, assessment of auditory-evoked ERPs revealed a substantial reduction in the amplitude and increased latency of ERPs in Mecp2 T158A/y and Mecp2 −/y mice, suggesting that there are deficits in information processing in the brain similar to those observed in women with RTT 24, 25 , in autism 20, 21 and in other disorders including schizophrenia 18 . Further studies are needed to address the neuronal mechanisms that underlie these deficits in ERP response.
Our data suggest that disturbances in event-related power and phase locking also occur in MeCP2 mouse models and may be involved in the etiology of RTT. In humans and animal models, changes in the power and phase locking of neuronal responses coordinate neuronal activity across different brain regions. These changes are involved in the development and efficacy of motor, perceptual and memory tasks, and deficits in neuronal oscillations are consistently observed in neurological disorders in which these functions are impaired 18, 43 . Our finding that both low-and high-frequency event-related oscillations were disrupted led us to hypothesize that deficits in local and long-distance neuronal circuitry occur following MeCP2 dysfunction. The neurophysiological mechanisms that lead to disturbances in these oscillations are not known, but may involve the reduced neuronal connectivity that leads to a redistribution of neuronal activity away from excitation and toward inhibition as observed in Mecp2 −/y mice [15] [16] [17] . Furthermore, given the importance of event-related neuronal responses in the development of the nervous system 44 , their disruption before symptom presentation may augment the deficits in neuronal activity caused by MeCP2 dysfunction. Indeed, Mecp2 T158A/y mice did not exhibit developmental increases in event-related power or phase locking suggestive of stagnation in the developmental of neuronal circuits. Moreover, our finding that event-related changes in power and phase locking occurred in Mecp2 T158A/y mice with no behavioral npg a r t I C l e S symptoms suggests that disruptions in neuronal networks may precede the behavioral RTT-like phenotypes. The identification of the mechanisms that lead to these disturbances will provide valuable insights into the pathogenesis of RTT and the neuronal networks underlying the manifestation of behavioral phenotypes in RTT. In summary, using Mecp2 T158A/y mice, we uncovered a previously unknown role for T158 in the pathogenesis of RTT and revealed an alternative strategy for restoring MeCP2 function. These mice provide an in vivo animal model for assessing therapeutic efficacy in preclinical trials. Moreover, given that ERP studies can be readily performed in humans, assessment of ERP and the changes in oscillation and phase locking may serve as a valuable biomarker for evaluating RTT phenotypes.
METhODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/natureneuroscience/.
Note: Supplementary information is available on the Nature Neuroscience website.
